Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study
IrAEs may serve as a surrogate for treatment response to neoadjuvant chemoimmunotherapy in early TNBC. Additionally, racial and age-based differences in treatment response suggest underlying immunologic or biologic variation. These findings highlight the importance of diverse cohort representation in immunotherapy studies and warrant validation in prospective trials.
Authors
- Michelle Sterpi (ORCID: https://orcid.org/0000-0002-1252-5838)
- Nechama Dreyfus
- Yungtai Lo
- Harjot Gill
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- Montefiore Einstein Comprehensive Cancer Center
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1007/s10549-026-07930-8
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00